Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,066 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Vascular Disease Clear all
Recruiting Phase 2 Interventional

Repurposing Valsartan May Protect Against Pulmonary Hypertension

NCT06053580
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder
Interventions
Valsartan 40 mg, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

NCT01728220
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

NCT00833703
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 2 Interventional Results available

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

NCT03528902
View directory record Official record
Conditions
Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
Interventions
Tamoxifen, Placebo Oral Tablet
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 3, 2026, 12:27 PM EDT
Active, not recruiting Phase 2 Interventional

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Cook IVC Filter Study

NCT02046096
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Günther Tulip® Vena Cava Filter, Cook Celect® Vena Cava Filters
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 3, 2026, 12:27 PM EDT
Active, not recruiting Not applicable Interventional

Implementation of Neuro Lung Protective Ventilation

NCT03243539
View directory record Official record
Conditions
Acute Brain Injury, Traumatic Brain Injury, Intracerebral Hemorrhage, Stroke, Cerebral Edema, Anoxic Brain Injury
Interventions
Lung Protective Ventilation
Procedure
Lead sponsor
Colin Grissom
Other
Eligibility
18 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 3, 2026, 12:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

NCT01143480
View directory record Official record
Conditions
Asthma, Atherosclerosis, Metabolic Syndrome, Insulin Resistance, Cancer
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 3, 2026, 12:27 PM EDT
Completed No phase listed Observational

Ventricular and Pulmonary Vascular Reserve After the Fontan Operation

NCT03853837
View directory record Official record
Conditions
Heart Failure, Congenital Heart Disease
Interventions
rest-exercise echocardiography
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 3, 2026, 12:27 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Interventions
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Drug · Combination Product
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.

NCT01179334
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo, Sildenafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Aurora, Colorado • Columbus, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

NCT00352430
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Nitric Oxide/INP Pulse Delivery, Nitric Oxide/INO Pulse Delivery
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 3, 2026, 12:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

NCT02690064
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Acute Antioxidant, Chronic Antioxidant, Placebo
Dietary Supplement · Other
Lead sponsor
Augusta University
Other
Eligibility
7 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis

NCT02169219
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Glucocorticoids, Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

Treatment of Wegener's Granulomatosis With Cyclophosphamide

NCT00001155
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

NCT01149668
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic
Interventions
PCI-24781
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Lafayette, Indiana • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 3, 2026, 12:27 PM EDT
Recruiting Not applicable Interventional

Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies

NCT02043691
View directory record Official record
Conditions
Juxtarenal Aortic Aneurysm, Suprarenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Penetrating Aortic Ulcer, Aortic Arch Aneurysm, Aortic Dissection
Interventions
Cook Custom Aortic Endograft, Zenith t-Branch Endovascular Graft, Surgeon-Modified Endograft
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 3, 2026, 12:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

NCT00899496
View directory record Official record
Conditions
Cancer
Interventions
immunological diagnostic method, physiologic testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

NCT03409588
View directory record Official record
Conditions
Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
Interventions
Adempas
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 3, 2026, 12:27 PM EDT
Completed No phase listed Observational

Outpatient Treatment of Low-risk Pulmonary Embolism

NCT02355548
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Outpatient Treatment of Pulmonary Embolism
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 3, 2026, 12:27 PM EDT
Not listed No phase listed Observational

Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

NCT01467791
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Hypertension
Interventions
Observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 3, 2026, 12:27 PM EDT
Terminated No phase listed Observational

Predicting Lung Injury From Transfusion in Patients With Liver Disease

NCT01756690
View directory record Official record
Conditions
Transfusion-related Acute Lung Injury, Chronic Liver Disease, Gastrointestinal Bleeding
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 3, 2026, 12:27 PM EDT
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 3, 2026, 12:27 PM EDT